Recce Pharmaceuticals (ASX:RCE) has secured human research ethics committee approval to allow up to 20 additional patients in its phase two clinical study to access Recce 327, a topical gel designed for diabetic foot infections (DFI), according to a Tuesday filing with the Australian bourse.

The study will run concurrently with Recce's phase three trial in Indonesia, which is expected to deliver results later in the year, with regulatory approval and commercial launch anticipated in the first half of 2026, the filing said.

Both studies aim to generate additional data to support future regulatory submissions, the filing added.